NFL Biosciences

Report Publication Announcement • Sep 9, 2024

NFL BIOSCIENCES: PARTICIPATION CALENDAR PHARMA EVENTS AND INSTITUTIONAL INVESTORS

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its calendar of events with pharmaceutical companies and institutional investors for the 2nd half of 2024.

Fvents	Dates*
International Partnering in Life-Sciences Society (IPLS) Annual Conference (Malaga, Spain)	16 to 18 september 2024
European Midcap Event (Paris, France)	1 & 2 october 2024
Seminar Portzamparc Biotech and Healthcare (video-conference)	8 & 9 october 2024
GIIN 2024 Impact Forum (Amsterdam, Netherlands)	23 & 24 october 2024
Bio-Europe (Stockholm, Sweden)	4 & 6 november 2024
Jefferies Healthcare Conference (London, United Kingdom)	19 & 20 november 2024

*The calendar is provided for information only and may be subject to change.

À propos de NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences ambition is to bring new, natural, safer and more effective the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easyto-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drup of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contacts

Bruno Lafont – info@nflbiosciences.com - 04 11 93 76 67

Agence Calyptus – nflbio@calyptus.net - 01 53 65 68 68